"Erythropoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
| Descriptor ID |
D004921
|
| MeSH Number(s) |
D12.644.276.374.410.240.150 D12.776.395.240.150 D12.776.467.374.410.240.150 D23.529.374.410.240.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Erythropoietin".
Below are MeSH descriptors whose meaning is more specific than "Erythropoietin".
This graph shows the total number of publications written about "Erythropoietin" by people in this website by year, and whether "Erythropoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 2 | 4 | 6 |
| 1997 | 2 | 2 | 4 |
| 1998 | 0 | 1 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 4 | 1 | 5 |
| 2005 | 7 | 1 | 8 |
| 2006 | 2 | 0 | 2 |
| 2007 | 3 | 1 | 4 |
| 2008 | 3 | 2 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 4 | 0 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Erythropoietin" by people in Profiles.
-
Association of Fluid Balance With Short- and Long-term Respiratory Outcomes in Extremely Premature Neonates: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 12 01; 5(12):e2248826.
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
-
Combination Therapy by Tissue-Specific Suicide Gene and Bevacizumab in Intramedullary Spinal Cord Tumor. Yonsei Med J. 2020 Dec; 61(12):1042-1049.
-
Human recombinant erythropoietin improves motor function in rats with spinal cord compression-induced cervical myelopathy. PLoS One. 2019; 14(12):e0214351.
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
-
Home Therapy to Reduce Office Visits for Patients with Chronic Kidney Disease and Anemia. Nephrol Nurs J. 2017 Jan-Feb; 44(1):29-33.
-
Administer but Do Not Dispense: Effect of Change in Medication Handling by Nurses on Outcomes of Home Dialysis Patients. Am J Med Sci. 2016 06; 351(6):595-600.
-
The incidence of ARDS and associated mortality in severe TBI using the Berlin definition. J Trauma Acute Care Surg. 2016 Feb; 80(2):308-12.
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.